Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Expert Highlights Biological Advancements in Bladder Cancer Field

October 3rd 2017

Brant Inman, MD, discusses the biology of bladder cancer, the evolving role of checkpoint inhibitors, and the future of chemotherapy in the disease.

Dr. Inman Discusses the Biology of Bladder Cancer

October 3rd 2017

Brant Inman, MD, surgical oncologist, urologic oncologist, Duke Cancer Center, discusses the biology of bladder cancer.

Dr. Zhang on the Impact of the LATITUDE Study in Prostate Cancer

October 3rd 2017

Tian Zhang, MD, a medical instructor in the Department of Medicine, Duke University School of Medicine, discusses the impact of the LATITUDE study in prostate cancer.

Dr. Zibelman on Determining Treatments for Patients with RCC

October 3rd 2017

Matthew R. Zibelman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses determining treatments for patients with renal cell carcinoma (RCC).

Dr. Geynisman on Sequencing of Agents for Kidney Cancer

October 3rd 2017

Daniel M. Geynisman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses challenges facing the sequencing of agents for patients with metastatic kidney cancer.

Expert Discusses Optimizing Sequence of Non-Hormonal Therapy in mCRPC

October 3rd 2017

Daniel J. George, MD, discusses the major questions practitioners are asking regarding optimizing upfront therapy for patients with mCRPC.

Dr. Hoffman-Censits on Biomarker Development in Urothelial Carcinoma

September 29th 2017

Jean Hoffman-Censits, MD, associate professor of Medical Oncology, Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center, discusses biomarker development in the field of urothelial carcinoma.

Successful ESMO Studies to Likely Trigger Sequencing Shakeup in RCC

September 29th 2017

Rana R. McKay, MD, discusses the promising findings from the CheckMate-214 and CABOSUN studies in renal cell carcinoma.

Dr. Uzzo on the Guidelines for the Management of Kidney Cancer

September 28th 2017

Robert G. Uzzo, MD, chair, Surgical Oncology, G. Willing "Wing" Pepper Chair in Cancer Research, senior vice president, Physician Services, president, Fox Chase Cancer Center Medical Group, Inc., professor of surgery, Temple University Health System, Fox Chase Cancer Center, discusses the guidelines for the treatment and management of patients with kidney cancer.

Dr. Plimack on Strategies for Developing Cure for Locally Advanced Urothelial Carcinoma

September 28th 2017

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses strategies for developing cures for patients with locally advanced urothelial carcinoma.

Bladder Cancer Paradigm Expanding to Include Immunotherapy Combos, Targeted Therapies

September 28th 2017

Terence Friedlander, MD, discusses the targeted therapies emerging in the field of bladder cancer, as well as immunotherapy combinations that are traveling through the pipeline.

PSMA-PET Agents Poised to Advance Imaging in Prostate Cancer

September 27th 2017

Thomas Hope, MD, discusses the novel technique PSMA-PET and how, if approved, it will significantly alter detection of biochemically recurrent prostate cancer.

Choueiri Covers CABOSUN Excitement and Beyond in RCC

September 27th 2017

Toni K. Choueiri, MD, sheds light on the excitement surrounding the CABOSUN and CheckMate-214 trials, and why the future of the renal cell carcinoma field lies in novel combination regimens.

Pal Provides Key ESMO Updates in GU Malignancies

September 26th 2017

Sumanta Kumar Pal, MD, discusses the scope of exciting genitourinary cancer data presented at the 2017 ESMO Congress, with a sharp focus on the CABOSUN and CheckMate-214 trials.

Radium-223 Plus Anti-VEGF Therapy Reduces Bone Turnover in Advanced RCC

September 26th 2017

Patients with advanced renal cell carcinoma with bone metastases had reductions in bone-turnover markers when treated with radium-223 dichloride and a VEGF inhibitor, although the incidence of symptomatic skeletal events remained high.

Longer Follow-Up Shows Survival Increase With Rocapuldencel-T in mRCC

September 26th 2017

Patients with metastatic renal cell carcinoma appeared to derive a substantial survival benefit with rocapuldencel-T, an immunotherapy made from dendritic cells.

Dr. McKay Discusses the CheckMate-214 Trial in RCC

September 26th 2017

Rana R. McKay, MD, medical oncologist, assistant professor, Moores Cancer Center at the University of California, San Diego, discusses the CheckMate-214 study in renal cell carcinoma.

Atezolizumab Approved in Europe for Lung, Bladder Cancer

September 25th 2017

The European Commission has granted regulatory approval to atezolizumab monotherapy for the treatment of patients with previously-treated locally advanced or metastatic non-small cell lung cancer and previously-treated locally advanced or metastatic urothelial carcinoma.

Expert Talks Optimizing ADT in Prostate Cancer

September 22nd 2017

Rahul Aggarwal, MD, discussed the success of recent studies of androgen-deprivation therapy in prostate cancer, as well as its future utilization in various stages of disease.

Dr. Bosse on Rationale Behind Study of VEGF Plus Radium-223 in RCC

September 21st 2017

Dominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses the rationale behind combining VEGF-targeted therapies and radium-223 dichloride (Xofigo) in metastatic renal cell carcinoma.